Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass.
Study Goal
The researchers aimed to evaluate the potential of N-Acetylcysteine, among other nutraceuticals, to aid in preserving bone mass by addressing key signaling pathways involved in bone health.
Results Summary
The study suggests that N-Acetylcysteine, when combined with other nutraceuticals and minerals, may help preserve bone health, though specific results for N-Acetylcysteine alone are not detailed. Many of these agents, including N-Acetylcysteine, have shown favorable effects on bone density in rodent models.
Population
Rodent models of bone loss (specific human population not mentioned).
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
ferulic acid | increase | Sirt1 activation | - | - | can be promoted | #1 |
N1-methylnicotinamide | increase | Sirt1 activation | - | - | can be promoted | #2 |
melatonin | increase | Sirt1 activation | - | - | can be promoted | #3 |
nicotinamide riboside | increase | Sirt1 activation | - | - | can be promoted | #4 |
glucosamine | increase | Sirt1 activation | - | - | can be promoted | #5 |
thymoquinone | increase | Sirt1 activation | - | - | can be promoted | #6 |
berberine | increase | AMPK | - | - | is a clinically useful activator | #7 |
metformin | increase | AMPK | - | - | is a clinically useful activator | #8 |
lipoic acid | increase | Nrf2 activity | - | - | can promote | #9 |
melatonin | increase | Nrf2 activity | - | - | can promote | #10 |
thymoquinone | increase | Nrf2 activity | - | - | can promote | #11 |
astaxanthin | increase | Nrf2 activity | - | - | can promote | #12 |
crucifera-derived sulforaphane | increase | Nrf2 activity | - | - | can promote | #13 |
pharmacological doses of biotin | increase | soluble guanylate cyclase (sGC) | - | - | can directly stimulate | #14 |
certain flavonols, notably quercetin | decrease | CK2 | - | high nanomolar concentrations that may be clinically relevant | can inhibit | #15 |
Many, though not all, of these agents | increase | bone density and structure | rodent models of bone loss | - | have shown favorable effects | #16 |
Complex nutraceutical regimens providing a selection of these nutraceuticals in clinically meaningful doses | increase | bone health | - | - | may have an important potential for preserving | #17 |
Concurrent supplementation with taurine, N-acetylcysteine, vitamins D and K2, and minerals, including magnesium, zinc, and manganese, plus a diet naturally high in potassium | increase | preserving bone health | - | - | may also be helpful | #18 |
There is a vast pre-clinical literature suggesting that certain nutraceuticals have the potential to aid the preservation of bone mass in the context of estrogen withdrawal, glucocorticoid treatment, chronic inflammation, or aging. In an effort to bring some logical clarity to these findings, the signaling pathways regulating osteoblast, osteocyte, and osteoclast induction, activity, and survival are briefly reviewed in the present study. The focus is placed on the following factors: the mechanisms that induce and activate the RUNX2 transcription factor, a key driver of osteoblast differentiation and function; the promotion of autophagy and prevention of apoptosis in osteoblasts/osteoclasts; and the induction and activation of NFATc1, which promotes the expression of many proteins required for osteoclast-mediated osteolysis. This analysis suggests that the activation of sirtuin 1 (Sirt1), AMP-activated protein kinase (AMPK), the Nrf2 transcription factor, and soluble guanylate cyclase (sGC) can be expected to aid the maintenance of bone mass, whereas the inhibition of the serine kinase CK2 should also be protective in this regard. Fortuitously, nutraceuticals are available to address each of these targets. Sirt1 activation can be promoted with ferulic acid, N1-methylnicotinamide, melatonin, nicotinamide riboside, glucosamine, and thymoquinone. Berberine, such as the drug metformin, is a clinically useful activator of AMPK. Many agents, including lipoic acid, melatonin, thymoquinone, astaxanthin, and crucifera-derived sulforaphane, can promote Nrf2 activity. Pharmacological doses of biotin can directly stimulate sGC. Additionally, certain flavonols, notably quercetin, can inhibit CK2 in high nanomolar concentrations that may be clinically relevant. Many, though not all, of these agents have shown favorable effects on bone density and structure in rodent models of bone loss. Complex nutraceutical regimens providing a selection of these nutraceuticals in clinically meaningful doses may have an important potential for preserving bone health. Concurrent supplementation with taurine, N-acetylcysteine, vitamins D and K2, and minerals, including magnesium, zinc, and manganese, plus a diet naturally high in potassium, may also be helpful in this regard.